Specialist, Cell Therapy Patient Operations - 6 month contractor role
BrainChild Bio
Summary
BrainChild Bio is seeking a highly motivated, detail-oriented Specialist to coordinate the end-to-end, time-sensitive patient cell supply chain for our autologous cell therapy products. This role will collaborate closely with internal stakeholders, external vendors, apheresis centers, and clinical sites to support seamless execution from order placement through drug product delivery.
Job description
The ideal candidate is a proactive and adaptable professional who thrives in a dynamic, fast-paced environment. They are comfortable managing day-to-day operations with precision. With a strong sense of ownership and a collaborative mindset, they are driven to deliver operational excellence that directly impacts patient outcomes.
Responsibilities
- Coordinate with clinical site study coordinators, apheresis centers, CDMOs, couriers, and internal stakeholders to maintain patient treatment schedules within established logistical and operational requirements.
- Execute day-to-day scheduling and cell logistics activities, coordinating patient treatment milestones from enrollment through drug product delivery.
- Support communication of scheduling updates, manufacturing milestones, product availability, and logistics requirements to clinical sites and internal stakeholders.
- Monitor patient scheduling and logistics activities and identify, communicate, and escalate scheduling conflicts, manufacturing delays, logistics risks, chain of identity concerns, or clinical site support needs to the Director of Patient Operations in a timely manner.
- Maintain accurate scheduling and logistics records and trackers in accordance with established Patient Operations procedures.
- This role may require participation in an on-call rotation and occasional work outside standard business hours to support time-sensitive patient and product activities.
Qualifications and Education Requirements
- One to two years of experience in the biotech or cell therapy industry
- Proven experience in scheduling, planning, and logistics coordination
- Solid understanding of GMP and GTP requirements
- Excellent analytical and problem-solving skills
- Exceptional attention to detail and a strong commitment to right-first-time execution
- Demonstrated ability to build and maintain strong cross-functional and external relationships
- Self-starter with flexibility, creativity, and the ability to thrive in a dynamic startup environment
Preferred qualifications
- Experience supporting autologous cell therapy clinical trials, working with chain of identity and chain of custody processes, coordinating temperature-controlled shipments, and using scheduling or case management systems.
This contractor must be able to work afternoon hours in Pacific Standard Time (PST).
Requirements
- One to two years of experience in the biotech or cell therapy industry
- Proven experience in scheduling, planning, and logistics coordination
- Solid understanding of GMP and GTP requirements
- Excellent analytical and problem-solving skills
- Exceptional attention to detail and a strong commitment to right-first-time execution
- Demonstrated ability to build and maintain strong cross-functional and external relationships
- Self-starter with flexibility, creativity, and the ability to thrive in a dynamic startup environment
- Experience supporting autologous cell therapy clinical trials, working with chain of identity and chain of custody processes, coordinating temperature-controlled shipments, and using scheduling or case management systems.
Company overview
BrainChild Bio is a clinical-stage biotechnology company pioneering the development of CAR T-cell therapies specifically designed for tumors in the central nervous system (CNS). Founded in 2023 as a spin-out from Seattle Children's Hospital, the company adopts a "kids-first" approach, prioritizing pediatric brain tumors with plans to expand its technology platform to adult indications including glioblastoma and brain metastases. The company's initial focus is on diffuse intrinsic pontine glioma (DIPG), an incurable type of childhood brain cancer, leveraging over a decade of translational research conducted at Seattle Children's Therapeutics. BrainChild Bio is advancing a next-generation CAR T-cell therapy platform that integrates synthetic technologies including multiplex targeting, enhanced potency controls, and remote switching capabilities to optimize therapeutic application in CNS tumors. The company's leadership team includes industry veterans with extensive experience in immunotherapy development, including CEO Steven Brugger, who previously led Affinivax through its $3.3 billion acquisition by GSK, and Chief Scientific Officer Dr. Michael Jensen, a pioneer in cancer immunotherapy with over 200 patents in cell and gene therapy. BrainChild Bio represents a significant advancement in addressing the unmet medical need for effective treatments for CNS tumors, particularly in pediatric populations.